Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (11-20 of 189) with videos related to

Pageof 19
Sort By:
Biometrics|March 14, 2002
Monitoring the rates of composite events with censored data in phase II clinical trialsYing Kuen Cheung, Peter F Thall
Journal of the Royal Statistical Society. Series C, Applied Statistics|September 10, 2013
Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute LeukemiaAbdus S Wahed, Peter F Thall
European Journal of Cancer (Oxford, England : 1990)|February 20, 2007
Practical Bayesian adaptive randomisation in clinical trialsPeter F Thall, J Kyle Wathen
Contemporary Clinical Trials|August 22, 2020
Comparison of Phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteriaAndrew G Chapple, Peter F Thall
Blood|February 1, 2003
New designs for phase 2 clinical trialsElihu H Estey, Peter F Thall
Pharmaceutical Statistics|August 17, 2018
Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combinationAndrew G Chapple, Peter F Thall
Biometrics|September 2, 2004
Dose-finding based on efficacy-toxicity trade-offsPeter F Thall, John D Cook
Biometrics|June 28, 2019
Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"Andrew G Chapple, Peter F Thall
Clinical Trials (London, England)|October 7, 2017
A simulation study of outcome adaptive randomization in multi-arm clinical trialsJ Kyle Wathen, Peter F Thall
Statistics in Medicine|April 5, 2005
Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatmentsPeter F Thall, J Kyle Wathen
Pageof 19

Showing results (11-20 of 189) with videos related to

Sort By:
Pageof 19
Biometrics|March 14, 2002
Monitoring the rates of composite events with censored data in phase II clinical trialsYing Kuen Cheung, Peter F Thall
Journal of the Royal Statistical Society. Series C, Applied Statistics|September 10, 2013
Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute LeukemiaAbdus S Wahed, Peter F Thall
European Journal of Cancer (Oxford, England : 1990)|February 20, 2007
Practical Bayesian adaptive randomisation in clinical trialsPeter F Thall, J Kyle Wathen
Contemporary Clinical Trials|August 22, 2020
Comparison of Phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteriaAndrew G Chapple, Peter F Thall
Blood|February 1, 2003
New designs for phase 2 clinical trialsElihu H Estey, Peter F Thall
Pharmaceutical Statistics|August 17, 2018
Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combinationAndrew G Chapple, Peter F Thall
Biometrics|September 2, 2004
Dose-finding based on efficacy-toxicity trade-offsPeter F Thall, John D Cook
Biometrics|June 28, 2019
Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"Andrew G Chapple, Peter F Thall
Clinical Trials (London, England)|October 7, 2017
A simulation study of outcome adaptive randomization in multi-arm clinical trialsJ Kyle Wathen, Peter F Thall
Statistics in Medicine|April 5, 2005
Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatmentsPeter F Thall, J Kyle Wathen
Pageof 19